These reports show that the vaccine manufacturing processes used for clinical trials and for the general population both yielded comparable vaccines. The EMA reports show that 3/4

the work needed to demonstrate comparability was performed and that the vaccine from Process 2 met the necessary requirements. Available data contradicts the claim that the Pfizer-BioNTech COVID-19 vaccine that made it to the general population was inadequately tested. 4/4